Pharmaceuticals

Non Hodgkin Lymphoma (NHL) Market Forecast Highlighting Key Trends And Expansion Potential

May 1, 2026May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Non Hodgkin Lymphoma (NHL) Market Between 2026 And 2030?

Significant growth has been observed in the non hodgkin lymphoma (nhl) market size over recent years. It is projected to expand from $10.86 billion in 2025 to $11.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. This historical growth can be attributed to factors such as the rising incidence of nhl globally, advances in chemotherapy regimens, increasing healthcare expenditure, growing awareness of lymphatic cancers, and the expansion of oncology hospital infrastructure.

The non hodgkin lymphoma (nhl) market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $16.44 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.8%. This growth over the forecast period is fueled by several factors, including the expanding pipeline of targeted therapies, an increase in biologics approvals, the growing embrace of personalized medicine, broader market access in developing regions, and the rise in stem cell transplant procedures. Key trends influencing this period encompass the increased uptake of immunotherapy and targeted therapy, a greater reliance on combination treatment regimens, an enhanced emphasis on early and precise diagnosis, the development of personalized treatment protocols, and a move towards outpatient and home-based care models.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

What Leading Drivers Are Supporting The Non Hodgkin Lymphoma (NHL) Market Expansion?

The non-Hodgkin lymphoma market is expected to grow significantly, driven by the high occurrence of the condition. This cancer originates within the lymphatic system, a vital part of the body’s immune defense. The prevalence of non-Hodgkin lymphoma specifically refers to the count of individuals in a given population who are currently diagnosed with or living with the disease at a particular time. Non-Hodgkin lymphoma treatments are essential for improving outcomes for diagnosed individuals by effectively targeting and managing the cancer cells. For instance, in January 2023, data from the American Cancer Society, a US-based cancer health organization, showed that non-Hodgkin lymphoma accounts for 4% of all cancers and is anticipated to affect approximately 80,550 Americans in 2023, comprising 44,880 males and 35,670 females. The organization further estimates that 20,180 people will die in 2023 due to non-Hodgkin lymphoma. Thus, the substantial prevalence of non-Hodgkin lymphoma is a major impetus for the non-Hodgkin lymphoma market.

What Are The Key Segment Divisions In The Non Hodgkin Lymphoma (NHL) Market Segment Structure?

The non hodgkin lymphoma (nhl) market covered in this report is segmented –

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma

2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

What Emerging Trends Are Seen In The Non Hodgkin Lymphoma (NHL) Market?

Leading companies in the non-Hodgkin lymphoma market are increasingly focused on introducing advanced immunotherapies, such as Epcoritamab-bysp (EPKINLY), to achieve a competitive advantage. Epcoritamab-bysp (EPKINLY) is an investigational subcutaneous immunotherapy designed to target CD20-expressing B-cell malignancies, demonstrating promising results in clinical trials, particularly for relapsed or refractory B-cell non-Hodgkin lymphoma. For instance, in November 2023, AbbVie Inc., a US-based pharmaceutical company, obtained a breakthrough therapy designation (BTD) from the United States Food and Drug Administration for Epcoritamab-bysp (EPKINLY). This approval pertains to the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more prior therapies. Additionally, the European Medicines Agency (EMA) has validated a Type II application for epcoritamab (TEPKINLY) for the same indication. These advancements are supported by previously announced results from the Phase 1/2 EPCORE NHL-1 clinical trial. The trial assessed the safety and preliminary efficacy of subcutaneous epcoritamab in 128 adult patients with relapsed, progressive, or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma (NHL), including FL.

Which Organizations Are Engaged In The Non Hodgkin Lymphoma (NHL) Market?

Major companies operating in the non hodgkin lymphoma (nhl) market are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

Get The Full Non Hodgkin Lymphoma (NHL) Market Report:

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Which Region Is The Leading Market For The Non Hodgkin Lymphoma (NHL) Market?

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Non Hodgkin Lymphoma (NHL) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Browse Through More Reports Similar to the Global Non Hodgkin Lymphoma (NHL) Market 2026, By The Business Research Company

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795